Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -0.99% is 95% above its 5-year average of -19.13%, near the high end of its 5-year range (-452.28%–22.94%).
97.64% above its 12-month average of -41.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -96.93%.
EBITDA MARGIN
-0.99%
EBITDA MARGIN AVG TTM
-41.88%
EBITDA MARGIN AVG 3Y
6.56%
EBITDA MARGIN AVG 5Y
-19.13%
EBITDA MARGIN AVG 10Y
-168.77%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.64%
CURRENT VS 3Y AVG
-115.10%
CURRENT VS 5Y AVG
+94.83%
CURRENT VS 10Y AVG
+99.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BioStem Technologies, Inc.
Market Cap
$46.79M
EBITDA Margin
-0.99%
TTM Avg
-41.88%
3Y Avg
6.56%
5Y Avg
-19.13%
Market Cap
$45.20M
EBITDA Margin
-3807.96%
TTM Avg
-2001.11%
3Y Avg
-1442.90%
5Y Avg
-1442.90%
Market Cap
$49.50M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$49.96M
EBITDA Margin
-10794.00%
TTM Avg
-9994.66%
3Y Avg
-8986.60%
5Y Avg
-8678.68%
Market Cap
$50.25M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.51M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$42.41M
EBITDA Margin
-148.02%
TTM Avg
-167.05%
3Y Avg
-193.51%
5Y Avg
-252.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | $46.79M | -0.99% | -41.88% | 6.56% | -19.13% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.20M | -3807.96% | -2001.11% | -1442.90% | -1442.90% |
| biote Corp. (BTMD)vs › | $49.40M | 20.40% | 19.12% | 4.66% | 12.12% |
| Celularity Inc. (CELU)vs › | $49.50M | -203.44% | -129.78% | -288.25% | -438.27% |
| Clene Inc. (CLNN)vs › | $49.96M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Apollomics, Inc. (APLM)vs › | $50.51M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $42.41M | -148.02% | -167.05% | -193.51% | -252.90% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
Gross Margin
93.1%
EBITDA Margin
-1.0%
Operating Margin
-1.4%
Net Margin
-13.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -96.93% |
| 2026-03-31 | -136.00% |
| 2025-12-31 | 8.79% |
| 2025-09-30 | 14.38% |
| 2025-06-30 | 0.35% |
| 2025-03-31 | 7.31% |
| 2024-12-31 | 8.32% |
| 2024-09-30 | 11.32% |
| 2024-06-30 | 11.91% |
| 2024-03-31 | 11.12% |
| 2023-12-31 | -24.23% |
| 2023-09-30 | 16.28% |
| 2023-06-30 | -248.35% |
| 2023-03-31 | -265.38% |
| 2022-12-31 | -452.28% |
| 2022-09-30 | -62.23% |
| 2022-06-30 | 22.94% |
| 2022-03-31 | -22.03% |
| 2021-12-31 | -38.08% |
| 2021-09-30 | -59.54% |
| 2021-06-30 | -18.07% |
| 2021-03-31 | -30.00% |
| 2020-12-31 | -35.86% |
| 2020-09-30 | -113.88% |
| 2020-06-30 | -212.28% |
| 2020-03-31 | -25.22% |
| 2019-12-31 | -35.59% |
| 2019-09-30 | -150.30% |
| 2019-06-30 | -268.25% |
| 2019-03-31 | -407.59% |
| 2018-12-31 | -711.80% |
| 2018-09-30 | -434.34% |
| 2018-06-30 | -2428.61% |
| 2018-03-31 | -1906.20% |
| 2017-12-31 | -158.09% |
| 2017-09-30 | -2613.59% |
| 2017-06-30 | -1906.69% |
| 2017-03-31 | -1011.54% |
| 2016-12-31 | 1983.86% |
| 2016-09-30 | -1153.77% |
| 2016-06-30 | -1001.97% |
| 2016-03-31 | -308.95% |
| 2015-12-31 | -632.40% |
| 2014-12-31 | -62.36% |
| 2013-09-30 | 28.86% |
